Texas Heart Institute
Welcome,         Profile    Billing    Logout  
 30 Trials 
50 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perin, Emerson
ACORD, NCT00117936: Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

Not yet recruiting
2
150
NA
Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose, Placebo
CardioVascular BioTherapeutics, Inc.
Coronary Disease, Coronary Heart Disease, Myocardial Ischemia, Coronary Arteriosclerosis
03/22
03/23
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
NCT00314366: Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)

Completed
1
21
US
Stem Cell Therapy, NOGA Myostar catheter, Control (plasma)
Texas Heart Institute, CHI St. Luke's Health, Texas, Aldagen
Coronary Artery Disease
08/09
08/23
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II

Recruiting
N/A
380
Canada, US
Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
Neovasc Inc., Shockwave Medical, Inc.
Refractory Angina
06/25
12/28
Bracey, Arthur
RedeS, NCT03037164: INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

Recruiting
3
800
US
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Cerus Corporation
Anemia
10/25
01/26
Callahan, Christine C
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II

Recruiting
N/A
380
Canada, US
Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
Neovasc Inc., Shockwave Medical, Inc.
Refractory Angina
06/25
12/28
NCT05069558: Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

Active, not recruiting
N/A
450
Europe, Canada, US
Investigational PFO Closure Device, Standard of Care PFO Closure Device
Occlutech International AB
Stroke, Patent Foramen Ovale, PFO
11/25
10/26
AMIHOT III, NCT04743245: Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

Recruiting
N/A
434
US
TherOx DownStream System, PCI
TherOx
Acute Myocardial Infarction, STEMI
10/25
04/26
Rogers, Joseph
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
NCT06174103: BiVACOR® Total Artificial Heart Early Feasibility Study

Recruiting
N/A
5
US
BiVACOR TAH System
BiVACOR Inc.
Heart Failure, Biventricular Failure
08/25
12/26
Mallidi, Hari
NCT05047068: OCS Heart Perfusion Post-Approval Registry

Active, not recruiting
N/A
350
US
OCS Heart System
TransMedics
Transplant
12/25
12/29
Krajcer, Zvonimir
NCT05653336: PerQseal® Clinical Study

Active, not recruiting
N/A
149
Europe, US
PerQseal® Closure Device System
Vivasure Medical Limited
Percutaneous Large Hole Vascular Closure
12/24
06/25
Civitello, Andrew
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure

Recruiting
2
150
US
AB-1002, Gene Therapy, NAN-101
Asklepios Biopharmaceutical, Inc.
Congestive Heart Failure
10/26
12/30
Chen, James
EZH-301, NCT04204941 / 2019-003648-55: Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Checkmark Early data from P1b/3 trial for advanced epithelioid sarcoma at medical conference 2021
May 2021 - May 2021: Early data from P1b/3 trial for advanced epithelioid sarcoma at medical conference 2021
Recruiting
3
164
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Doxorubicin HCl, Tazverik®, Placebo
Epizyme, Inc.
Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma
01/29
01/30
NCT01191151: Web Based Orthopaedic Sports Medicine Registry

Terminated
N/A
12500
Europe, Canada, US, RoW
Arthrex, Inc.
Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip
07/23
07/23
Gregoric, Igor
NCT02232659: SynCardia 70cc TAH-t for Destination Therapy (DT)

Recruiting
N/A
38
US
70cc TAH-t for Destination Therapy
SynCardia Systems. LLC
Life-threatening, Biventricular Heart Failure, Ineligible for Cardiac Transplant
12/21
05/22
Taveras, Yanille
CLEAN-PE, NCT06189313: CLEANer Aspiration for Pulmonary Embolism

Recruiting
N/A
125
US
Cleaner Pro Thrombectomy System, Cleaner Vac Thrombectomy System
Argon Medical Devices, NAMSA
Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
02/26
05/26
Ono, Masahiro
NCT05100836: SURPASS Impella 5.5 Study

Active, not recruiting
N/A
1017
US
Impella 5.5
Abiomed Inc.
Cardiogenic Shock, Acute Decompensated Heart Failure
12/24
12/24
NCT05047068: OCS Heart Perfusion Post-Approval Registry

Active, not recruiting
N/A
350
US
OCS Heart System
TransMedics
Transplant
12/25
12/29
Costello, Brianna
NCT05316350: Withings ECG-app Study

Completed
N/A
685
Europe, US
Electrocardiogram recording
Withings, Syntactx
Atrial Fibrillation
08/23
08/23
Caceres, Lina
GenePHIT, NCT05598333: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects with Non-Ischemic NYHA Class III Heart Failure

Recruiting
2
150
US
AB-1002, Gene Therapy, NAN-101
Asklepios Biopharmaceutical, Inc.
Congestive Heart Failure
10/26
12/30
Sampaio, Sara
NCT02438306: CardiAMP™ Cell Therapy for Heart Failure Trial

Active, not recruiting
3
125
Canada, US
Autologous cell therapy, Sham
BioCardia, Inc.
Heart Failure, Systolic
12/24
12/26
Frank, Felicia
NCT03975829 / 2018-004459-19: Pediatric Long-Term Follow-up and Rollover Study

Active, not recruiting
4
165
Europe, Canada, Japan, US, RoW
dabrafenib, DRB436, trametinib, TMT212
Novartis Pharmaceuticals, Novartis Pharma AG
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
05/26
05/26
AUGMENT-102, NCT05326516: A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from AUGMENT-102 trial for relapsed/refractory leukemias
Completed
1
30
Canada, US
Revumenib, SNDX-5613, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Syndax Pharmaceuticals
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
07/24
07/24
Croce, Kevin
AGENT IDE, NCT06492174: A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort

Active, not recruiting
3
20
US
AGENT DCB 40 mm
Boston Scientific Corporation
In-Stent Restenosis
12/25
12/27
Ringer PTCA, NCT04862689: Investigation of the Ringer Perfusion Balloon Catheter

Completed
N/A
60
Canada, US
Ringer Perfusion Balloon Catheter
Vascular Solutions LLC
Coronary Stenosis
06/23
06/23
NCT04280029: SELUTION SLR™ 014 In-stent Restenosis

Active, not recruiting
N/A
418
Europe, Canada, US, RoW
SELUTION SLR™ DEB, Control
M.A. Med Alliance S.A., Iqvia Pty Ltd, Cordis Corporation
Coronary Restenosis
07/25
08/29
VITALYST EFS, NCT06132568: VITALYST Early Feasibility Study in High-Risk PCI Patients

Active, not recruiting
N/A
15
Europe, US
VITALYST System, Percutaneous Mechanical Circulatory Support
Boston Scientific Corporation
High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary
10/24
01/25
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II

Recruiting
N/A
380
Canada, US
Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
Neovasc Inc., Shockwave Medical, Inc.
Refractory Angina
06/25
12/28
NCT06358508: Sapphire 3 CTO Study

Recruiting
N/A
170
US
Sapphire 3 Coronary Dilatation Catheter
OrbusNeich, Avania
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
12/25
12/25
Mathuria, Nilesh
LESS-VT, NCT03490201: FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

Completed
N/A
592
Europe, US, RoW
Market Approved RF Ablation System, FlexAbility SE Ablation Catheter
Abbott Medical Devices
Ventricular Tachycardia
04/24
04/24
Kumar, Abhishek
OnTARGET, NCT04538625: Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Completed
3
287
US, RoW
Crofelemer 125 MG [Mytesi], Placebo
Napo Pharmaceuticals, Inc.
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
08/23
10/23
OCCLUDE, NCT06170619: Obsidio™ Conformable Embolic Registry

Recruiting
N/A
125
US
Obsidio™ Conformable Embolic
Boston Scientific Corporation
Hypervascular Tumors, Bleeding, Hemorrhage
06/25
06/25
CLEAN-PE, NCT06189313: CLEANer Aspiration for Pulmonary Embolism

Recruiting
N/A
125
US
Cleaner Pro Thrombectomy System, Cleaner Vac Thrombectomy System
Argon Medical Devices, NAMSA
Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
02/26
05/26
ALPHA LONG, NCT05799963: Study- BioMatrix AlphaTM Stent Study in Patients With CAD

Active, not recruiting
N/A
85
Europe
BioMatrix Alpha
Biosensors Europe SA
Coronary Artery Disease
07/25
03/26
Makam
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Postilian, Alex
NCT05316337: Withings ECG-Monitor Study

Completed
N/A
650
Europe, US
Electrocardiogram recording
Withings, Syntactx
Atrial Fibrillation
09/23
09/23
Worley, Amy
NCT05143177: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS)

Active, not recruiting
2/3
867
Canada, US
Evogliptin, DA-1229, Placebo
REDNVIA Co., Ltd.
Calcific Aortic Valve Disease
05/26
12/26
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation

Active, not recruiting
N/A
669
Europe, Canada, US
Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System
Boston Scientific Corporation
Persistent Atrial Fibrillation
03/25
03/25
Belknap, Anthony
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Recruiting
N/A
268
US
Aortix System, Aortix Pump
Procyrion
Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
07/25
12/25
NCT05069558: Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

Active, not recruiting
N/A
450
Europe, Canada, US
Investigational PFO Closure Device, Standard of Care PFO Closure Device
Occlutech International AB
Stroke, Patent Foramen Ovale, PFO
11/25
10/26
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Munson, Taylor
JUPITER, NCT05762302: The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("" TRIAL)

Recruiting
N/A
1316
US, RoW
MeMed BV test
MeMed Diagnostics Ltd.
Lower Respiratory Tract Infection
02/25
02/25
VITALYST EFS, NCT06132568: VITALYST Early Feasibility Study in High-Risk PCI Patients

Active, not recruiting
N/A
15
Europe, US
VITALYST System, Percutaneous Mechanical Circulatory Support
Boston Scientific Corporation
High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary
10/24
01/25
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II

Recruiting
N/A
380
Canada, US
Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
Neovasc Inc., Shockwave Medical, Inc.
Refractory Angina
06/25
12/28
Houston, Jada
NCT05143177: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS)

Active, not recruiting
2/3
867
Canada, US
Evogliptin, DA-1229, Placebo
REDNVIA Co., Ltd.
Calcific Aortic Valve Disease
05/26
12/26
Marbach, Jeffrey
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Recruiting
N/A
268
US
Aortix System, Aortix Pump
Procyrion
Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
07/25
12/25
Jackson, Joseph
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Recruiting
N/A
268
US
Aortix System, Aortix Pump
Procyrion
Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
07/25
12/25

Download Options